Recent public news highlights an insider sale by the CEO of NIKA, involving 2,000,000 shares sold in March 2025.

• On March 19, 2025, the CEO of NIKA sold 2,000,000 shares of the company’s stock, an insider sale disclosed publicly [N1].

NIKA’s business model leverages exclusive rights to patented pharmaceutical and dietary supplement products, supported by clinical trial history and strategic partnerships. The consolidation of ownership in Nika Europe, Ltd. and the planned construction of a pharmaceutical manufacturing facility could provide a foundation for scaling production and distribution. The company’s listing on OTCQB increases its visibility to investors. Insider activity, such as the CEO’s share sale, indicates active management of equity holdings. The company’s focus on niche products with potential therapeutic benefits may offer opportunities for market penetration as development progresses.

NIKA faces significant challenges including the absence of reported revenue and ongoing net losses, indicating limited current commercial traction. The company’s liquidity ratios as of December 31, 2025, are very low, suggesting potential short-term financial constraints. The small executive team and lack of formal insider trading policies reflect an early-stage organizational structure. The company’s reliance on exclusive rights agreements and partnerships exposes it to risks if these relationships change or if product development does not advance. The CEO’s large insider share sale may raise questions about insider confidence. Overall, the company’s business model and financial position present execution and funding risks.

NIKA’s moat is primarily based on exclusive rights agreements and patented technologies for its pharmaceutical products and dietary supplements. The company holds long-term exclusive rights to manufacture and distribute products such as Thymus Nuclear Glycoprotein (TNG) and supplements like Carotilen and Physiolong. Additionally, joint business agreements with other entities provide access to patented medicinal product platforms. The planned pharmaceutical manufacturing facility through its majority-owned subsidiary Nika Europe, Ltd. may enhance production capacity and market presence. However, the company’s small scale, limited financial resources, and early stage of development constrain its competitive advantages.

• Financial Risk: The company reported no revenue for fiscal year 2024 and a net loss of $76,398 for fiscal year 2025, with very low liquidity ratios (current ratio 0.07, cash ratio 0.01) as of December 31, 2025, indicating potential financial constraints.
• Operational Risk: NIKA operates with only two executive officers and has not adopted formal insider trading policies, which may reflect limited organizational maturity and governance controls.
• Business Model Risk: The company’s business depends heavily on exclusive rights agreements and partnerships for product development and distribution, which may be subject to change or termination.
• Market and Execution Risk: There is no disclosed revenue or market presence data, and the company is in early stages of building manufacturing capacity through Nika Europe, Ltd., which may delay commercialization.

• NIKA PHARMACEUTICALS, INC. is a pharmaceutical company incorporated in Colorado in 2000, currently focusing on production and distribution of pharmaceutical and dietary supplement products under exclusive rights agreements.
• The company holds a 15-year exclusive rights agreement with VITAL FE Joint Stock Company for production and distribution of Thymus Nuclear Glycoprotein (TNG), a product with clinical trial history related to HIV treatment.
• NIKA has exclusive rights agreements for two dietary supplements, Carotilen and Physiolong, with MICAR 11 LTD, both aimed at supporting cellular metabolism, immune function, and recovery.
• The company has a joint business agreement with Immunotech Laboratories BG, Ltd. to develop medicinal products based on the Inactivated Pepsin Fraction platform, protected by multiple U.S. patents, with a 9-year renewable term.
• NIKA merged with Nika BioTechnology, Inc. in 2024, consolidating ownership and increasing its stake in Nika Europe, Ltd. to 80%, which is preparing to build a pharmaceutical manufacturing facility.
• The company’s common stock is listed on OTCQB under the ticker NIKA as of December 2024.
• As of December 31, 2025, NIKA had no revenue reported for fiscal year 2024 and reported a net loss of $76,398 for fiscal year 2025, with zero basic and diluted earnings per share.
• Liquidity ratios as of December 31, 2025, show a current ratio of 0.07 and a cash ratio of 0.01, indicating limited short-term liquidity.
• NIKA operates with two executive officers and has not adopted formal insider trading policies as of the end of 2025, relying on general federal securities laws.
• There are no material legal proceedings pending or threatened against the company or its officers as of the latest filings.
• On March 19, 2025, the CEO sold 2,000,000 shares of the company’s stock, an insider sale disclosed publicly.